| Literature DB >> 35052562 |
Varun Jaiswal1, Shweta Chauhan1, Hae-Jeung Lee1,2,3.
Abstract
Pachyrhizus erosus (L.) Urb. is an underutilized crop plant belonging to the Fabaceae family. In recent years, the plant received huge attention and was introduced in different countries owing to properties such as a high nutritional content, its nitrogen-fixing abilities, and different biological activities such as its antioxidant, immune modulation, anticancer, anti-diabetes, anti-osteoporosis, antiviral, and antiaging affects, among others. In this review, an attempt has been made to comprehensively compile the biological activities of the plant to provide a panoramic view of the current efforts and further directions, which may lead to the development of pharmacological applications. This information will be helpful in creating interest towards P. erosus and it may be useful in developing the plant for medical applications and/or as a functional food. More than 50 phytochemicals have been reported from the plant, which belong to different chemical classes such as triterpenoids, organic acid, flavonoids, and fatty acids. Numerous biological activities were reported from the plant through in vivo, in vitro, ex vivo, and human studies. However, well-defined clinical studies are still lacking for the establishment of any biological properties that could be further developed. Suggestions for the further development of P. erosus, according to current knowledge about the different biological properties, has also been provided.Entities:
Keywords: Pachyrhizus erosus; anti-diabetes; anticancer; antioxidants; flavonoids; jicama; pharmacological activities; phytochemicals
Year: 2021 PMID: 35052562 PMCID: PMC8773301 DOI: 10.3390/antiox11010058
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Phytochemicals with potential antioxidant properties identified in P. erosus.
| Sr. | Name | Type | Amount/Yield | Sample | Activity | References |
|---|---|---|---|---|---|---|
| 1 | 12a-Hydroxydolineone | Rotenoids | 31 μg/g | Seeds | Against HSV types 1 and 2 | [ |
| 2 | 12a-Hydroxyerosone | Rotenoids | 6 μg/g | Seeds | NA | [ |
| 3 | 12a-hydroxypachyrhizone | Rotenoids | 36 μg/g | Seeds | Against HSV types 1 and 2 | [ |
| 4 | 12a-Hydroxyrotenone | Rotenoids | 9 μg/g | Seeds | Anticancer and against HSV types 1 and 2 | [ |
| 5 | Dehydroneotenone | Isoflavone | 4 μg/g | Seeds | Antifungal activity | [ |
| 6 | Dolineone | Rotenoids | 60 μg/g | Seeds | Antifungal activity | [ |
| 7 | Erosone | Isoflavonoids | Seeds | Antifungal activity | [ | |
| 8 | Munduserone | Rotenoids | Seeds | NA | [ | |
| 9 | Neodulin | 3-arylcoumarin | 3.4% μg/g | Seeds | NA | [ |
| 10 | Neotenone | Isoflavonoids | 41 μg/g | Seeds | NA | [ |
| 11 | Pachyrrhizine | Isoflavonoids | 35 μg/g | Seeds | Antifungal activity | [ |
| 12 | Pachyrrhizone | Rotenoids | 117 μg/g | Seeds | Antifungal activity | [ |
| 13 | Pachyrrhisomene | Pterocarpan | 04.7 μg/g | Seeds | NA | [ |
| 14 | Rotenone | Rotenoids | 153 μg/g | Seeds | Anticancer and antifungal activity | [ |
| 15 | (8,9)-Furanyl-pterocarpan-3-ol | Pterocarpan | 141.05 μg/g | Tuber | Antioxidant and skin whitening | [ |
| 16 | 2-Butoxy-2,5-bis(hydroxymethyl)-tetrahydrofurane-3,4-diol | Other | Tuber | Antioxidant and skin whitening | [ | |
| 17 | 4-(2-(Furane-2-yl)ethyl)-2-methyl-2,5- dihydro-furane-3-carbaldehyde | Other | Tuber | Antioxidant and skin whitening | [ | |
| 18 | 5-Hydroxy-daidzein-7-O- | Isoflavonoids | Tuber | Skin whitening | [ | |
| 19 | Daidzein-7- | Isoflavonoids | 329.93 ± 10.00 μg/g | Tuber | Antioxidant and skin whitening - | [ |
| 20 | Genistin | Isoflavonoids | Tuber | Antioxidant and skin whitening | [ | |
| 21 | Kaikasaponin III | Triterpenoid glycosides | 69 μg/g | Tuber | NA | [ |
| 22 | Daidzein | Isoflavonoids | 2356.10 ± 38.47 μg/g | Tuber juice | Antioxidant and skin whitening | [ |
| 23 | Genistein | Isoflavonoids | 1655.30 μg/g | Tuber juice | NA | [ |
| 24 | Formononetin | 7-hydroisoflavones | 65.13 ± 3.01 μg/g | Leaves | NA | [ |
| 25 | Gentisic acid | Dihydroxybenzoic acid | 69.03 ± 1.00 μg/g | Leaves | NA | [ |
| 26 | l-Phenylalanine | Amino acid | 16,654.43 ± 43.52 μg/g | Leaves | NA | [ |
| 27 | Malonyl genistin | Glycosyloxyisoflavone | 683.77 ± 12.69 μg/g | Leaves | NA | [ |
| 28 | Malonyldaidzin | Glycosyloxyisoflavone | 9853.90 ± 44.28 μg/g | Leaves | NA | [ |
| 29 | Aromatic acid | 612.83 ± 2.02 μg/g | Leaves | NA | [ | |
| 30 | Aromatic acid | 161.63 ± 1.52 μg/g | Leaves | NA | [ | |
| 31 | Salicylic acid | Aromatic acid | 58.83 ± 2.57 μg/g | Leaves | NA | [ |
| 32 | Vitexin | Flavones | 1970.12 ± 9.22 μg/g | Leaves | NA | [ |
| 33 | Isobavachalcone | Flavonoids | 34.3 μg/g | Leaves | Anticancer | [ |
| 34 | Wighteone | Flavonoids | 2.9 μg/g | Leaves | Anticancer | [ |
| 35 | Prunin | Flavonoids | 2.7 μg/g | Leaves | NA | [ |
| 36 | Orientin | Flavonoids | 50 μg/g | Leaves | NA | [ |
| 37 | Erosusone | Flavonoids | 2 μg/g | Leaves | Anticancer | [ |
| 38 | 3-episedumoside F1 | Megastigmane glycoside epimer | 20 μg/g | Leaves | NA | [ |
Figure 1Phytochemicals reported form P. erosus.
Figure 2Different biological activities of P. erosus through different extracts and forms reported in literature.
Different biological activity through in vitro studies.
| Sr. No. | Activity | Model/Method | Dose/Duration | Component Used | Result | Reference |
|---|---|---|---|---|---|---|
| 1 | Antioxidant/anti-aging | DPPH antioxidant assay | 6.25–200 (µg/mL) | IC50 = 84.09 ± 4.87 (µg/mL) | [ | |
| DPPH antioxidant assay | 6.25–200 (µm/mL) | IC50 = 98.30 ± 1.30 (µm/mL) | [ | |||
| Tyrosinase activity inhibition | 3.13–100 (µg/mL) | IC50 = 194.51 ± 7.63 (µm/mL) | [ | |||
| Tyrosinase activity inhibition | 3.13–100 (µg/mL) | IC50 = 97.05 ± 0.86 (gm/mL) | [ | |||
| Scavenging activity on ABTS radical (IC50) | 100 µL at different concentrations | IC50 = 1825.16 ± 22.87 (µg/mL) | [ | |||
| Scavenging activity on ABTS radical (IC50) | 100 µL at different concentrations | IC50 = 1711.71 ± 58.09 (µg/mL) | [ | |||
| DPPH antioxidant assay | 100 µL at different concentrations | IC50 = 1215.65 ± 65.99 (µgm/mL) | [ | |||
| DPPH antioxidant assay | 100 µL at different concentrations | IC50 = 998.10 ± 117.71(µg/mL) | [ | |||
| 2 | Anti-diabetes | α-glucosidase inhibitory assay | 0.05–0.25 (µg/mL) | IC50 = 0.083 ± 0.004 (mg/mL) | [ | |
| α-amylase inhibitory activity | 0.05–0.25 (µg/mL) | IC50 = 0.091 ± 0.017 (mg/mL) | [ | |||
| 3 | Immune modulation | ELISA is used to measure antibodies on HB4C5 cells and splenocytes | Sample conc. 0.1–100 (mg/mL) | The production levels of immunoglobulin, i.e., IgM, IgG, and IgA, as well as cytokines, were significantly enhanced | [ | |
| Phagocytosis activity J774.1 cell/P-Mac cells | 1.69, 6.75, and 27 mg/mL | An increase in phagocytosis activity and the production of pro-inflammatory cytokines was observed | [ | |||
| 4 | Antiviral | Plaque reduction assay was performed for | 100 µL at different concentrations | Compounds isolated from seeds | 12a-hydroxydolineone and 12a-hydroxypachyrrhizone found to have activity against both HSV-1 and -2 | [ |
| 5 | Antifungal | Growth inhibitory effects on fungi | 0.5, 2.0, 5.0, and 10 mg/mL | −2 to −15% (inhibition) | [ | |
| Growth inhibitory effects on fungi | 2.0, 5.0 and 10 mg/mL | 5.4 to −64.9% (inhibition) | [ | |||
| Growth inhibitory effects on fungi | 250 µg/mL | Compounds isolated from seeds | 2.81–56.2% (inhibition) | [ | ||
| Inhibitory activities on the growth of different fungi were determined by microspectrophotometry | 15 μg/ml | SPE10 (a dimeric plant defensin protein) from the seeds of | IC50 of 15 μg/mL | [ | ||
| Inhibitory activities on the growth of fungi ( | 6.2–12.5 μg | PaAFP (the protein isolated and purified from the | [ | |||
| 6 | Anticancer | Human hepatoma cell | 0.06 mL/well | Pachyerosin protein isolated from seeds of | IC50 of 0.050 ± 0.004 nM for pachyerosin(immunotoxin) and IC50 of 117.92 ± 10.21 nM for pachyerosin | [ |
| The viability of K562 cells determined by the MTT assay | 0.06 mL/well | The | [ |
Different biological activities of P. erosus through in vivo, ex vivo, and human studies.
| Sr. No. | Activity | Model | Dose Duration | Substance | Result | References |
|---|---|---|---|---|---|---|
| 1 | Anti-diabetes | Male ICR mice induced for diabetes mellitus by streptozotocin | (200 mg/kg) at 0, 30, 60, and 120 min | The AUC for the glucose response of | [ | |
| Male C57BL/KsJ-db/db mice; blood glucose and glycosylated hemoglobin levels | (0.5 g/100 g diet) 6 weeks | HbA1c values for | [ | |||
| Plasma insulin level | (0.5 g/100 g diet) 6 weeks | Plasma insulin values for | [ | |||
| Homeostatic index of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) | (0.5 g/100 g diet) 6 weeks | HOMA-IR values for | [ | |||
| Intraperitoneal glucose tolerance test (IPGTT) | (0.5 g/100 g diet) 6 weeks | IPGTT outcomes were improved in db/db-JCE group mice compared to db/db-control group mice | [ | |||
| Hepatic glycogen assay | (0.5 g/100 g diet) 6 weeks | Hepatic glycogen concentration values for | [ | |||
| Male Bagg and Albino (BALB)/c mice fed with HSD | 10% and 25% | Blood glucose level was significantly lower in JF groups (HSD + JF 10%, and HSD + JF 25%) as compared with HSD group, starting at 4th week of treatment ( | [ | |||
| Body weight and adipose tissue measurements | 10% and 25% PTF in 8-week diet | The body weight gain was significantly lower in JF 25% group, but not in JF 10% group, as compared with HSD group ( | [ | |||
| 24 male DDY strain mice | Yogurt, 2 mL for 7 days | Probiotic treatment group vs. using | [ | |||
| BALB (Bagg and Albino)/c mice | 10% and 25% with high-fat diet for 8 weeks | Blood glucose was significantly lower in the treated groups and normal group. The pancreatic tissue was protected from high-fat diet induced islet hyperplasia and hypertrophy in mice treated the treatment group | [ | |||
| 40–50-year-old people; 10 people as a case group and 10 people as a control group | Dose of 250 g (150 mL) per day | 259.90 mg/dL, then 185.40 mg | [ | |||
| Male and female | 7 mL juice with glucose (50% concentration 2.5 gm/kg) | The mean increase of blood glucose level was | [ | |||
| 2 | Immune modulation | Male BALB/c mice induced with hepatitis B vaccine | 25, 50, and 100 mg/kg | Treatment stimulated phagocytotic macrophages, NO production from peritoneal macrophages, and in vivo lymphocyte proliferation. Enhancements in phagocytic capacity index characterized by increased NO, IL-10, and TNF-production | [ | |
| Male BALB/c mice induced with hepatitis B vaccine | 100 and 200 mg/kg for 18 days | Methanolic and ethyl ether fraction (FAEF) from the tuber of | Enhanced the innate immune response and IgG production. The immune enhancing effect was observed with FAEF treatment with increased phagocytic activity, and stimulation of both TNF-α and IL-6 production | [ | ||
| Female BALB/c mice | 6.75 or 27 mg/kg body weight for 14 days | BFE may activate the adaptive immune | [ | |||
| BALB/c mice | 6.75 mg/kg and 27 mg/kg for 7 days | BFE could activate macrophages by increasing the phagocytosis activity and production of pro-inflammatory cytokines in mouse P-Mac in vitro and in vivo | [ | |||
| BALB/c mice | 6.75 and 27 mg/mL | Tuber fiber extract | Phagocytosis activity percentage of P-Mac ex vivo increased from 32.1 ± 1.9 to 42.6 ± 4.6 ( | [ | ||
| 3 | Phytoesterogenic activity | Female Sprague–Dawley rat | 1.5 mL | The myometrium in rats with | [ | |
| BALB/c female | 0.3, 0.6, and 0.9 g/kg for 24 days | Treatment caused proliferation of the uterine endometrium and myometrium layers and increased the number of uterine glands | [ | |||
| Rats (Female) | Three oral doses: 70, 140, and 280 mg/200 g every day for 14 days | Tuber ethanol extract | Significantly increased the number of antral follicles and endometrial stromal follicles; increased the amount of endometrial epithelium was observed | [ | ||
| 4 | Anti-osteoporosis | Female Sprague–Dawley rats | 200, 400, and 800 mg/kg for 28 days | Ethyl acetate extract of | Femoral length, tibiae length, bone density of bone ash; content of calcium, and bone ash content of phosphorus increased to 32.51 ± 0.92 mm, 37.25 ± 0.57 mm, 1.441 ± 0.064 g/cm3, 50.02 ± 6.55%, and 32.73 ± 1.09%, respectively | [ |
| 5 | Cardio protection | Human platelet aggregation study and blood pressure measurement | 500 mL | The ex vivo collagen-induced platelet aggregation was significantly attenuated, as well as | [ | |
| 6 | Central nervous system depressant activity | Swiss albino mice of either sex | 75 and 150 mg/kg | Ethanolic seed extract of | Ethanolic extract of seeds of | [ |
| 7 | Preventive effects on gastric ulcers | Swiss | 100, 300, and 600 mg/kg | Reduced the number of ulcers, increased the ratio of protection, and repaired the cells in gastric histopathology | [ | |
| 8 | Insecticidal activity | Insecticide | 0.1–2.0 (% | Oviposition deterrent indices | [ | |
| Larvae and adults of | Up to 100 mg/mL | Lethal concentration 50 (LC50) of 16.22 ± 0.20 µg/mL and LC50 value of 91.41 ± 0.49 µg/mL | [ |